



**Mailing Address:**  
ADAP Advocacy  
PO Box 846  
Nags Head, NC 27959

**Office Address:**  
1630 Connecticut Ave, NW  
Suite 500  
Washington, DC 20009

**CEO:**  
Brandon M. Macsata  
Washington, D.C.

**Board of Directors:**

**Co-Chair**  
Guy Anthony  
Brooklyn, NY

**Co-Chair**  
Wanda Brendle, Moss, R.N.  
Winston-Salem, NC

**Secretary**  
Lisa Johnson-Lett  
Birmingham, AL

**Treasurer**  
Robert "Bobby" L. Dorsey, Esq.  
La Plata, MD

Erin Darling, Esq.  
Washington, DC

Lyne Fortin, B.Pharm, MBA  
Montreal, Canada

Maria Mejia  
Tamarac, FL

Shabbir Imber Safdar  
San Francisco, CA

Jennifer Vaughan  
Watsonville, CA

Marcus A. Wilson  
Orlando, FL

**Directors Emeritus:**  
Michelle Anderson  
William Arnold – *in memoriam*  
John D. Kemp, Esq.  
Gary Rose – *in memoriam*  
Joyce Turner Keller  
Rani Whitfield, M.D.

[adapadvocacy.org](http://adapadvocacy.org)

## ADAP Advocacy & Legacy Health Endowment Publish 340B White Paper

### ***REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program***

For Immediate Release:  
February 6, 2026

Media Contact:  
[info@adapadvocacy.org](mailto:info@adapadvocacy.org)

WASHINGTON, D.C. – ADAP Advocacy, today, in partnership with the California-based Legacy Health Endowment, released a thought-provoking white paper focusing on what's at stake if the federal government fails to reform the 340B Drug Pricing Program, which is now the second largest federal prescription drug program in the United States, behind Medicare Part D. It reassesses the 340B framework through the patient experience, calling for improved oversight and accountability. The white paper, "***REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program***," makes the case for the new 340B rebate model, highlighting the AIDS Drug Assistance Program as the Gold Standard among covered entities, which already largely operates under this model.

Brandon M. Macsata, CEO of ADAP Advocacy, stated: "**The Trump Administration has called for needed changes to the 340B Program. It proposed a rebate system to replace the current upfront payments from drug companies to covered entities, which have caused waste and fraud, mostly among hospitals. We enthusiastically endorse this change to enhance accountability and transparency to better serve patients with chronic health conditions, such as HIV, cancer, cystic fibrosis, diabetes, and so many others.**"

A 340B Rebate Model would put patients *before* providers, allowing them—for the first time—to see whether they receive the benefit of lower 340B prices when they pay out of pocket at the pharmacy counter.

Jeffrey Lewis, President & CEO of the Legacy Health Endowment, said: "**Viewing the program through a contemporary lens allows for a much-needed reassessment of its direction and goals, guided by legislative action.**"

To learn more about ADAP Advocacy or the 340B Program, please email [info@adapadvocacy.org](mailto:info@adapadvocacy.org).

#####

***About ADAP Advocacy:*** The ADAP Advocacy mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community members, health care providers, government officials, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient education programs, and foster greater community collaboration.

***About Legacy Health Endowment:*** Legacy Health Endowment provides funding and technical support to create healthcare solutions and facilitate improved wellness within Stanislaus and Merced Counties.